Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy

医学 结直肠癌 内科学 肿瘤科 化疗 完全响应 新辅助治疗 随机对照试验 临床试验 梅德林 贝伐单抗 外科 直肠癌 直肠 氟尿嘧啶 护理标准 风险评估 结肠疾病
作者
Yu Shen,Mingtian Wei,Yazhou He,Tinghan Yang,Xiangbing Deng,Qingbin Wu,H R Chen,Rui Fan,Yiqian Liu,Qingyun Li,Feifei Li,Xiafei Gu,Zi-Jian Lu,Meng Qiu,Wenjian Meng,Dan Jiang,Ziqiang Wang
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (7): 1293-1301 被引量:5
标识
DOI:10.1158/1078-0432.ccr-25-3774
摘要

PURPOSE: Neoadjuvant chemotherapy (NCT) has been accepted as the standard management for locally advanced rectal cancer (LARC) without high-risk factors. However, many patients experience poor pathologic response, necessitating early-prediction tools. We investigated dynamic circulating tumor DNA (ctDNA) analysis for early response monitoring in patients with LARC undergoing NCT. EXPERIMENTAL DESIGN: In this biomarker substudy of the multicenter randomized COPEC trial, 153 patients with low-/intermediate-risk LARC were enrolled. Plasma samples (n = 526) were collected at baseline and after each cycle of NCT. ctDNA was analyzed via tumor-informed sequencing. Patients were classified by dynamic status into high-risk (delayed/no clearance and recurred positive) and low-risk (early clearance and persistent negative) groups. Poor response was defined as pathologic tumor regression grade (pTRG) 3 or distant metastasis. The association between ctDNA status and responses was analyzed. RESULTS: No patient with high-risk ctDNA dynamics achieved a major pathologic response (pTRG 0-1). The poor response rate was 59.4% in the high-risk group versus 12.4% in the low-risk group (P < 0.001). High-risk dynamic ctDNA status was a strong independent predictor of poor response (OR = 11.69; 95% confidence interval, 5-27.25; P < 0.001). Both delayed/no clearance (OR = 12.64; P < 0.001) and recurred positivity (OR = 8.91; P < 0.001) were significant risk factors. A single preoperative ctDNA-positive result also predicted poor response (OR = 11.27; P < 0.001). CONCLUSIONS: Dynamic ctDNA monitoring identifies patients with LARC at high risk for NCT failure as early as two cycles into treatment, which can form the basis for an adaptive trial design and eventual personalization of therapy selection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Fooler完成签到,获得积分10
刚刚
朴素幻巧发布了新的文献求助10
刚刚
冷少完成签到,获得积分10
1秒前
嗷嗷完成签到,获得积分10
1秒前
3秒前
时平谊发布了新的文献求助10
5秒前
二柱子完成签到 ,获得积分10
5秒前
5秒前
Lucky完成签到,获得积分10
7秒前
丘比特的应助被温柔梦易采纳,获得10
7秒前
8秒前
liu完成签到,获得积分10
10秒前
王成鑫完成签到 ,获得积分10
10秒前
时平谊发布了新的文献求助200
11秒前
u924435完成签到,获得积分10
12秒前
北北完成签到 ,获得积分10
12秒前
1212122发布了新的文献求助10
13秒前
活泼的访云完成签到,获得积分10
14秒前
14秒前
鹿呦完成签到 ,获得积分10
15秒前
123完成签到 ,获得积分10
16秒前
promise完成签到 ,获得积分10
16秒前
CH完成签到,获得积分10
17秒前
Richard完成签到,获得积分10
17秒前
陶醉白梅完成签到,获得积分20
17秒前
18秒前
从容的罡完成签到,获得积分10
18秒前
FashionBoy的应助被丁一航采纳,获得10
19秒前
fsy完成签到,获得积分10
19秒前
Prophet发布了新的文献求助10
20秒前
安小安完成签到,获得积分10
20秒前
20秒前
21秒前
无足鸟完成签到,获得积分10
21秒前
22秒前
Samsara完成签到 ,获得积分10
23秒前
执着访文完成签到,获得积分10
23秒前
zr发布了新的文献求助10
24秒前
毅诚菌完成签到,获得积分10
24秒前
阿业发布了新的文献求助10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186629
求助须知:如何正确求助?哪些是违规求助? 9574913
关于积分的说明 21838832
捐赠科研通 7784206
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559183
邀请新用户注册赠送积分活动 2481582